Prolactin secreting pituitary tumors in men

Endocrinologist

Volumn 11, Issue 2, 2001, Pages 105-111

  Danila, Daniel C ^a   Klibanski, Anne ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; QUINAGOLIDE; TESTOSTERONE;

CELL DEATH; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GONADOTROPIN RELEASE; GONADOTROPIN SECRETING CELL; HEADACHE; HUMAN; HYPOGONADISM; INFERTILITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTIN BLOOD LEVEL; PROLACTIN SECRETING CELL; PROLACTINOMA; REVIEW; SEXUAL DYSFUNCTION; SYMPTOM; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; TUMOR VOLUME; VISUAL FIELD DEFECT;

EID: 0035072987     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200103000-00006     Document Type: Review

References (20)

1. Age-related and gender-related occurrence of pituitary adenomas
2. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study
3. Primary medical therapy of micro- and macroprolactinomas in men
4. Prolactin secreting adenoma in 22 men
5. Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)
6. Prolactinomas in men: Clinical characteristics and the effect of bromocriptine treatment
7. Hyperprolactinaemia in males: A heterogeneous disorder
8. Management of prolactinomas
9. Hyperprolactinemia in males with and without pituitary macroadenomas
10. Hyperprolactinemia in men with asthenozoospermia, oligozoospermia, or azoospermia
11. Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels
12. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas
13. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: Circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone
14. Osteoporosis in men with hyperprolactinemic hypogonadism
15. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism
16. Prolactinomas in children and adolescents: Clinical presentation and long-term follow-up
17. Prolactinomas in male and female patients: A comparative clinicopathologic study
18. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline
19. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
20. Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results